Sigma-2 receptor/TMEM97 agonist PB221 as an alternative drug for brain tumor.

Chia-Chi LiuChing-Fang YuShu-Chi WangHsueh-Yin LiChiu-Min LinHsia-Han WangCarmen AbateChi-Shiun Chiang

Published in: BMC cancer (2019)

This study demonstrates that the sigma-2 receptor agonist PB221 has the potential to be an alternative chemotherapeutic drug for brain tumors with comparable side effects as the current standard-of-care drug, temozolomide.

Keyphrases

heavy metals
healthcare
drug induced
emergency department
risk assessment
human health
chronic pain
health insurance